CDP-Choline Sodium
CAS 33818-15-4
Purity≥98%
Citicoline sodium powder for CDP-choline formulations and sodium-salt specification matching
PathGene supplies citicoline sodium powder (CDP-choline sodium, CAS 33818-15-4), distinct from citicoline CAS 987-78-0. The specification lists purity ≥98% and assay 98–102%. MOQ is 1 kg; standard packaging is 25 kg/carton, with smaller-order packing arranged separately. Batch COA and evaluation samples support identity, assay and formulation testing. nutrition & functional ingredients
Quote / sample & delivery
Key Specifications
| Product Positioning | Citicoline sodium powder for CDP-choline formulations and sodium-salt specification matching |
| Application Scenarios | formulation development |
| CAS Number | 33818-15-4 |
| Purity | ≥98% |
| Molecular Formula | C₁₄H₂₅N₄NaO₁₁P₂ · xH₂O |
| Molecular Weight | 510.31 g/mol (anhydrous moiety) |
| Appearance | Refer to the batch COA |
| Solubility | Evaluate dissolution at the target formulation concentration |
| Storage | Follow the supplied batch label and storage instructions |
| Shelf Life | 2 years under the specified storage conditions |
Procurement & delivery
Supply details confirmed by intended use, volume and target market
Citicoline sodium (CAS 33818-15-4) is the sodium salt of CDP-choline. PathGene Biotech supplies this material under an in-house specification with a purity requirement of ≥98%. The supplied COA identifies the material as C14H25N4NaO11P2·xH2O; 510.31 g/mol refers to the anhydrous moiety. It is a separate product from citicoline CAS 987-78-0, so salt identity, water content and assay basis should be checked when specifying or comparing materials. Product image: AI-generated ingredient illustration; actual batch appearance is subject to the sample and COA. For oral-solution or syrup development, the raw-material COA pH result is not a finished-formula pH recommendation. Screen concentration, excipients, solution clarity, assay and related substances during processing and storage. The target formula, packaging and preservation system require their own stability and microbiological evaluation.
Citicoline Sodium Bulk Supply
PathGene supplies Citicoline Sodium, CAS 33818-15-4, with specification ≥98%.
Ingredient Identity
The sodium salt of CDP-Choline, with its own CAS identity and quality documentation, supplied in 25 kg cartons.
Batch Quality Documentation
Batch COA supports the quality evaluation of Citicoline Sodium and the agreed purchasing specification.
Evaluation Samples
Request Citicoline Sodium samples for incoming-quality evaluation and project trials.
Supply and Packaging
MOQ: 1 kg. Packaging options: 25 kg/carton.
Test items, specifications and results for the listed batch are shown here. View or request a COA in the quality documents section.
Batch No.
PG02N-260714
Test date
2026-07-15
Specification
In-house
Pack size
25 kg/carton
Storage
Follow the supplied batch label and storage instructions
Conclusion
Conforms
| Test Item | Specification | Result |
|---|---|---|
| Appearance | White crystalline powder | Off-white powder |
| Identification | Positive reaction; HPLC retention time and IR spectrum match reference | Complies |
| Solution clarity and color | Clear and colorless | Complies |
| Purity | ≥98% | 99.9% |
| Assay | 98.0–102.0% | 99.5% |
| Loss on drying | ≤6.0% | 2.4% |
| pH | 6.0–7.5 | 6.88 |
| 5′-CMP | ≤0.3% | 0.090% |
| Other individual impurity | ≤0.2% | Complies |
| Total of other impurities | ≤0.7% | Complies |
| Methanol | ≤0.3% | Complies |
| Ethanol | ≤0.5% | Complies |
| Acetone | ≤0.5% | Complies |
| Chloride | ≤0.05% | Complies |
| Iron | ≤0.01% | Complies |
| Ammonium | ≤0.05% | Complies |
| Free phosphate | ≤0.1% | Complies |
| Heavy metals | ≤5 ppm | Complies |
| Arsenic | ≤1 ppm | Complies |
| Total plate count | ≤1000 CFU/g | Complies |
| Yeast and mold | ≤100 CFU/g | Complies |
| E. coli | Negative | Not detected |
| Salmonella | Negative | Not detected |
| Bacterial endotoxins | ≤0.30 EU/mg | Complies |
Request a reviewed COA through the quality documents section and confirm its product form and batch.
Hard capsules
Powders
Softgels
Tablets
Sublingual tablets
Oral dissolving films
Check sodium salt separately from free citicoline; sodium-salt mass, citicoline equivalents and water basis are different measures.
99.9%
Purity
99.5%
Assay
Complies
Other individual impurity
PG02N-260714 · Results apply to this lot; interpret purity, assay and water on their respective bases.
Composition candidates, processing sequences and tests support pilot design. Confirm candidate excipients and processes using this material in the actual finished formulation.
Study combinations, individual-ingredient mechanisms and product precedents are distinguished; expand each entry for scope and pilot-development checks.
Marketed oral solutions explicitly use citicoline as the sodium salt. Define the active-moiety declaration, concentration and excipient system before selecting the raw-material specification.
Expand research and formulation notes +Collapse research and formulation notes −Development rationale: Marketed oral solutions explicitly use citicoline as the sodium salt. Define the active-moiety declaration, concentration and excipient system before selecting the raw-material specification.
Evidence scope: AEMPS product information confirms the marketed dosage form; it does not certify PathGene material or establish equivalence of a new formulation.
Pilot checks: Retain individual-ingredient, blend and carrier controls; check uniformity and post-process assays before packaged samples, documenting study formulations separately from new candidates.
View original research or document ↗Assess the full raw-material and finished-product requirements for the intended process. An endotoxin compliance result alone does not demonstrate sterility or suitability for injection.
Expand research and formulation notes +Collapse research and formulation notes −Development rationale: Assess the full raw-material and finished-product requirements for the intended process. An endotoxin compliance result alone does not demonstrate sterility or suitability for injection.
Evidence scope: AEMPS lists a citicoline sodium injectable presentation. Application evidence is distinct from the qualification of this supplied grade.
Pilot checks: Retain individual-ingredient, blend and carrier controls; check uniformity and post-process assays before packaged samples, documenting study formulations separately from new candidates.
View original research or document ↗Literature-Supported Research Directions
Human oral CDP-choline research examined changes in circulating choline and uridine, providing a basis for studying precursor availability for membrane phospholipid synthesis. Salt form and formulation equivalence require separate assessment.
Citation: Wurtman et al. (2000). Effect of oral CDP-choline on plasma choline and uridine levels in humans.View source
An early human phosphorus magnetic resonance spectroscopy study observed changes in selected brain phospholipid metabolites after oral citicoline. These findings support investigation of phospholipid turnover; metabolic-marker changes alone do not establish clinical efficacy.
Citation: Babb et al. Psychopharmacology (2002), 161:248–254.View source
A 12-week placebo-controlled trial in 100 adults aged 50–85 with age-associated memory impairment reported improvements in secondary episodic and composite memory outcomes using a specific branded citicoline ingredient. This supports further research, not direct clinical validation of PathGene citicoline sodium.
Citation: Nakazaki et al. Journal of Nutrition (2021), 151:2153–2160.View source
Note: For ingredient R&D and scientific information; findings depend on model, dose, formulation and population and do not constitute a treatment claim or efficacy guarantee.
Lead Time
3–5business days
Standard products are generally in stock; confirm the exact lead time with us.
Minimum Order
1 kg
Samples, pilot trials, and commercial volumes are supported.
Foil Pouch
Sealed, moisture-protective inner packaging
Fiber Drum
Standard outer packaging for bulk transport
Bulk Shipping
Palletized and stretch-wrapped for protection
Ambient storage: foil pouch + fiber drum; temperature controlled: foil pouch + insulated box/carton. Confirm by product.
Custom packaging: Custom foil bags or HDPE drums, GMP label printing, and export documentation are available. Contact us for a quote.Images are packaging illustrations.
Certifications
Purity and assay are separate COA items: the specification is ≥98% for purity and 98–102% for assay. Batch PG02N-260714 reports 99.9% purity, 99.5% assay and 2.4% loss on drying. These are batch results, not minimum guarantees for every future batch. Confirm the analytical and calculation basis before comparing suppliers. Its endotoxin result is reported as Complies against ≤0.30 EU/mg, not as a numerical measured concentration or an external test result.
Citicoline sodium capsule formulation: screen the powder with the intended carrier or flow aid, measure blend uniformity and capsule fill-weight variation, and assay samples from multiple blend and filling positions. Account for water content and the batch assay basis when calculating ingredient loading. Citicoline sodium tablet formulation: compare direct compression with a dry-granulation pilot. Track flow, compactability, hardness, friability and disintegration. If wet granulation or effervescent processing is considered, measure assay and related substances before and after water and heat exposure; select moisture-protective packaging using finished-tablet stability results. Citicoline sodium powder sachets and beverage formulation: first measure dissolution at the intended concentration. In the full formula, evaluate pH, clarity, colour, taste and compatibility with acids, sweeteners and other ingredients. Measure assay and related substances after the proposed heating and holding process and during storage in the intended container. Powder sachets also require blend-uniformity and moisture testing. Development records should identify the chemical form, lot, assay reporting basis, composition, mixing order, processing conditions and packaging. These are pilot-development checks, not a validated finished formula or a finished-product shelf-life claim.
Yes. CDP choline sodium and citicoline sodium refer to the sodium salt supplied here, CAS 33818-15-4. Citicoline without the sodium-salt designation is a separate product, CAS 987-78-0. Use this sodium-salt specification and lot COA when comparing quotations or calculating formulation loading.
MOQ: 1 kg. Send quantity, destination, application, packaging and documentation requirements. PathGene will provide a project quotation and supply schedule.
Specify citicoline sodium CAS 33818-15-4 separately from citicoline CAS 987-78-0. The sodium salt and water content affect identity and mass-based assay comparisons; do not substitute one solely on the CDP-choline abbreviation.
Citicoline sodium (CDP-choline sodium, CAS 33818-15-4) powder has a purity specification of ≥98% and an assay range of 98–102%, with 25 kg/carton packaging. The lot COA reports purity, assay, water and other agreed quality items separately for buyer review.
Citicoline sodium purity and assay are separately reported measurements. Review each method, reference standard, water correction and calculation basis. A purity percentage does not automatically equal the active-component fraction by powder mass.
The supplied COA identifies C14H25N4NaO11P2·xH2O. The listed 510.31 g/mol is for the anhydrous moiety; use the batch water or loss-on-drying result and specified assay basis when assessing the supplied material.
The in-house specification lists purity ≥98% and assay 98–102%. Batch PG02N-260714 reports 99.9% and 99.5%, respectively. Request the COA for the offered batch.
COA PG02N-260714 records an endotoxin result compliant with a limit of ≤0.30 EU/mg. This is a compliance result for that limit, rather than a measured concentration. Sterility or third-party testing requirements need their own tests and reports.
Citicoline sodium has a raw-material MOQ of 1 kg and standard 25 kg/carton packaging. Evaluation samples can be requested separately for identity, assay and formulation testing. Confirm the bulk order’s pack configuration and lead time with the supply arrangement.
Batch PG02N-260714 reports pH 6.88 against a raw-material specification of 6.0–7.5. This does not define a stable pH window for a syrup or oral solution. Test the actual formula at its intended concentration, pH and processing temperature, and monitor clarity, assay, impurities and microbial quality over the proposed storage period. Buffer, sweetener and preservative compatibility must be evaluated in the same formula.
Test blend uniformity, powder flow, fill-weight variation and moisture. Verify assay in samples from multiple filling stages using the batch reporting basis.
Test powder flow, compactability, tablet hardness, friability, disintegration and assay retention. Evaluate related substances after any wet or heated processing and test moisture protection in the finished pack.
Measure dissolution at the intended concentration, then assess pH, clarity, taste, excipient compatibility, assay and related substances during processing and storage. Establish the shelf life using the complete formula in its intended packaging.
Documents are subject to product and batch availability; third-party reports are provided only when applicable.
Quality documents
The specification sheet defines acceptance limits. The COA shows actual batch results, which may vary by batch. Third-party reports are provided only for products or batches that have been independently tested.
Stable acceptance criteria · Available on request
Actual test data · Check the COA for the applicable batch
Related Products
Citicoline (CDP-Choline) Powder
Glutathione (Reduced) Powder
Interested in CDP-Choline Sodium?
Our R&D team will respond to your inquiry or sample request within 24 hours.
Scan to add WeChat
Alex Huang · Mon–Fri 9am–6pm CST
